{
    "Trade/Device Name(s)": [
        "Rightest Blood Glucose Monitoring System GM700S",
        "Rightest Blood Glucose Monitoring System GM700SB"
    ],
    "Submitter Information": "Bionime Corporation",
    "510(k) Number": "K190564",
    "Predicate Device Reference 510(k) Number(s)": [
        "K140210"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "February 22, 2019",
    "Summary Letter Received Date": "March 5, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Rightest Blood Glucose Monitoring Meter GM700S",
        "Rightest Blood Glucose Monitoring Meter GM700SB"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical sensor",
        "Amperometric method",
        "FAD-Glucose dehydrogenase enzyme chemistry"
    ],
    "Methodologies": [
        "Electrochemical detection"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution",
        "Lancing device",
        "Sterile lancet"
    ],
    "Document Summary": "FDA 510(k) summary for Rightest Blood Glucose Monitoring System GM700S and GM700SB for quantitative self-testing of glucose in capillary whole blood by individuals with diabetes",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from fingertips, forearm or palm; intended for self-testing by individuals with diabetes at home to monitor effectiveness of diabetes control; not for diagnosis, screening, or neonatal use; alternative site testing only during steady-state glucose",
    "fda_folder": "Clinical Chemistry"
}